TMCnet News
John Perkins to become new CEO BPL Holdings(ENP Newswire Via Acquire Media NewsEdge) ENP Newswire - 01 May 2014 Release date- 30042014 - LONDON, - BPL (Bio Products Laboratory) Holdings, a global biotherapeutics company, today announced that Kim Bjoernstrup has decided to step down from his role as Chief Executive Officer. Mr. Bjoernstrup will continue as an advisor to the company. John Perkins will become the new CEO, effective May 1. In addition to becoming CEO, Mr. Perkins will also join BPL's Board of Directors. Devin O'Reilly, director of the Board of BPL Holdings, said: 'On behalf of the Board, we want to thank Kim for his significant contributions to BPL and for successfully setting the company up for future growth. We're grateful to have benefitted from his leadership, and we look forward to his continued contribution as an advisor.' Kim Bjoernstrup commented: 'It has been an exciting time to be CEO of BPL. I believe the company is on a strong footing and I am excited for its future prospects. I look forward to ensuring a smooth transition for John as he settles into his new role.' Mr. O'Reilly added: 'John will make an outstanding CEO. He has deep and proven operational expertise specific to the plasma derived therapeutics industry.' Mr. Perkins joins BPL with 20 years of operating experience. Previously, he was the executive vice president for Global Commercial Operations at Talecris Biotherapeutics where he was responsible for the $1.6B commercial business. He also served on the Board of Centric Health Resources. Prior to Talecris, Mr. Perkins held roles as an operating executive at Cerberus Capital and as an executive at General Electric. (c) 2014 Electronic News Publishing - |